Acquire the license to the best health content in the world
Contact Us

April 2012 Briefing - Nephrology

Here are what the editors at HealthDay consider to be the most important developments in Nephrology for April 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Afinitor Approval Expanded to Include Benign Kidney Tumors

FRIDAY, April 27 (HealthDay News) -- Afinitor (everolimus) is the first drug to be approved by the U.S. Food and Drug Administration to treat benign kidney tumors among people with tuberous sclerosis complex (TSC), the agency said in a news release.

National Cancer Institute

Pathway Involved in Kidney Stone Formation Identified

TUESDAY, April 24 (HealthDay News) -- A gene previously linked to an increased risk of developing kidney stones is part of a calcium-sensitive pathway that regulates calcium absorption in the kidney, according to a study in the April 18 issue of The EMBO Journal.

Abstract
Full Text (subscription or payment may be required)

New Fibrate Use Ups Serum Creatinine Levels in Elderly

TUESDAY, April 17 (HealthDay News) -- For elderly adults, new fibric acid derivative (fibrate) use is associated with an increase in serum creatinine levels, in hospitalizations for these levels, and in nephrologist consultations, according to a study published in the April 17 issue of the Annals of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

Evidence Lacking for Value of CKD Screening and Monitoring

TUESDAY, April 17 (HealthDay News) -- There is no evidence that screening and monitoring for chronic kidney disease (CKD) improves clinical outcomes, according to research published in the April 17 issue of the Annals of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Herbal Carcinogen Linked to Urothelial Cancer in Taiwan

FRIDAY, April 13 (HealthDay News) -- A carcinogen produced by Aristolochia plants, which are commonly used in herbal remedies in Taiwan, is associated with signature types of DNA damage linked to aristolochic acid in Taiwanese patients with urothelial carcinoma of the upper urinary tract (UUC), according to a study published online April 9 in the Proceedings of the National Academy of Sciences.

Abstract
Full Text

Tivozanib Exhibits Antitumor Activity in Renal Cancer

TUESDAY, April 10 (HealthDay News) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma (RCC), according to research published online April 9 in the Journal of Clinical Oncology.

Abstract
Full Text (subscription or payment may be required)

Medical Malpractice Claims Incur Substantial Defense Costs

WEDNESDAY, April 4 (HealthDay News) -- Defense costs for medical malpractice claims vary among specialties and are higher for claims that result in indemnity payments, according to a letter published in the April 5 issue of the New England Journal of Medicine.

Full Text

Physician's Briefing